AnaptysBio has spun out its biotech operations into an independent public company called First Tracks Biotherapeutics. The new entity is expected to start trading on April 20, according to company announcements.
The spinout represents a strategic restructuring for AnaptysBio, allowing the parent company to focus on its core operations while establishing First Tracks as a separate public entity. This move follows a trend of biotech companies optimizing their corporate structures through strategic separations.